/ no comments
Eli Lilly and Company; Incyte Corporation
Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study
/ no comments
Eli Lilly and Company; Incyte Corporation
Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study
No comments:
Post a Comment